Edition:
United States

Northwest Biotherapeutics Inc (NWBO.OQ)

NWBO.OQ on NASDAQ Stock Exchange Capital Market

0.45USD
28 Jul 2016
Change (% chg)

$-0.00 (-0.07%)
Prev Close
$0.45
Open
$0.45
Day's High
$0.54
Day's Low
$0.42
Volume
182,948
Avg. Vol
148,756
52-wk High
$12.10
52-wk Low
$0.42

Summary

Name Age Since Current Position

Linda Powers

59 2012 Chairperson of the Board, President, Chief Executive Officer

Leslie Goldman

70 2011 Senior Vice President - Business Development

Anthony Maida

61 2013 Senior Vice President - Clinical Research

Marnix Bosch

55 2011 Chief Technical Officer

Alton Boynton

71 2012 Chief Scientific Officer, Director

Susan Bayh

55 2016 Independent Director

Cofer Black

2016 Independent Director

Robert Farmer

75 2009 Independent Director

Jerry Jasinowski

72 2012 Independent Director

Navid Malik

46 2012 Independent Director

Lisa Sher

IR Contact Officer

Biographies

Name Description

Linda Powers

Ms. Linda F. Powers is Chairperson of the Board, President, Chief Executive Officer of Northwest Biotherapeutics, Inc. She has served as the Chairperson of our Board of Directors since her appointment on May 17, 2007 and Chief Executive Officer since June 8, 2011. Ms. Powers served as a managing director of Toucan Capital Fund II from 2001 to 2010, and Toucan Capital Fund III thereafter. She also has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. She is a Board member of M2GEN (an affiliate of Moffitt Cancer Center), the Chinese Biopharmaceutical Association, and the Rosalind Franklin Society. She was the Chair of the Maryland Stem Cell Research Commission for the first two years of the state’s stem cell funding program, and has served an additional four years on the Commission. She served for several years on a Steering Committee of the National Academy of Sciences, evaluating government research funding, and has been appointed to three Governors’ commissions created to determine how to build the respective states’ biotech and other high-tech industries. For more than six years, She taught an annual internal course at the National Institutes of Health for the bench scientists and technology transfer personnel on the development and commercialization of medical products. She serves on the boards of several private biotechnology companies. She holds a B.A. from Princeton University, where she graduated magna cum laude and Phi Beta Kappa. She also earned a J.D., magna cum laude, from Harvard Law School. We believe Ms. Powers’ background and experience make her well qualified to serve as a Director.

Leslie Goldman

Mr. Leslie J. Goldman is Senior Vice President - Business Development of Northwest Biotherapeutics, Inc. Prior to joining us, Mr. Goldman was a partner at the law firm of Skadden, Arps for over 30 years, specializing in a wide array of advanced technologies and their commercialization. Mr. Goldman also serves as an advisor to a number of other technology companies. In addition, for eight years, Mr. Goldman served as Chairman of the Board of a group of TV stations in four mid-size cities across the country.

Anthony Maida

Dr. Anthony E. Maida, Ph.D., is Senior Vice President, Clinical Research of Northwest Biotherapeutics, Inc.He originally joined our company in June 2011, as Chief Operating Officer. During 2013, Dr. Maida moved into the position of SVP, Clinical Research, reflecting his focus on the Company’s Phase III clinical trial program in the US, in which he had been playing a central role throughout 2012 and 2013 to date. Dr. Maida brings more than 20 years’ experience in building oncology companies, with expertise in the business, financial, clinical and regulatory aspects of, and the underlying science of, oncology business and clinical trials. Over these two decades, Dr. Maida has held positions as Chairman, CEO, COO, CSO, CFO and VP Business Development. Among these experiences, he served as CEO of CancerVax Corporation, an early leader in cancer vaccines. In that role, he was responsible for conducting multi-hundred patient, multi-center clinical trials with the company’s cancer vaccines. Prior to joining us, Dr. Maida was serving as global head of oncology for a leading contract research organization that manages clinical trials in the U.S. and internationally.

Marnix Bosch

Dr. Marnix L. Bosch Ph.D, is Chief Technical Officer of Northwest Biotherapeutics, Inc. He joined NWBT in 2000, and has been serving as our Chief Technical Officer for a number of years. In this capacity, he plays a key role in the preparation and submission of our regulatory applications, as well as ongoing development of our product lines, and ongoing development and/or acquisition of new technologies. Dr. Bosch led the process of designing the protocols, and managed the successful preparation and submission of our Investigational New Drug (IND) applications for FDA approval to conduct clinical trials for prostate cancer, brain cancer, ovarian cancer and multiple other cancers. He also led the processes for other regulatory submissions in both the U.S. and abroad (including the successful applications for orphan drug status in both the U.S. and Europe for DCVax-L for brain cancer). He spearheaded the development of our manufacturing and quality control processes, and is working with Cognate BioServices, Inc. on next-generation further development of these processes. Prior to joining us in 2000, Dr. Bosch worked at the Dutch National Institutes of Health (RIVM) as head of the Department of Molecular Biology, as well as in academia as a professor of Pathobiology. He has authored more than 40 peer-reviewed research publications in immunology and virology, and is an inventor on several patent applications on dendritic cell product manufacturing.

Alton Boynton

Dr. Alton L. Boynton ,Ph.D. is Chief Scientific Officer, Director of Northwest Biotherapeutics, Inc.Dr. Boynton co-founded our company, has served as our Chief Scientific Officer and a Director since our inception in 1998, was appointed our Chief Operating Officer in August 2001, was appointed President in May 2003, and served as Chief Executive Officer from June 2007 to June 2011. Prior to founding our company, He headed the Molecular Oncology research lab at the Pacific Northwest Research Foundation (the original foundation of Bill Hutchinson, from which the Fred Hutchinson Cancer Center was spun off). He also served as Director of the Department of Molecular Medicine of Northwest Hospital from 1995 to 2003 where he coordinated the establishment of a program centered on carcinogenesis. Prior to joining Northwest Hospital, He was Associate Director of the Cancer Research Center of Hawaii, The University of Hawaii, where he also held the positions of Director of Molecular Oncology of the Cancer Research Center and Professor of Genetics and Molecular Biology. He received his Ph.D. in Radiation Biology from the University of Iowa in 1972. We believe Dr. Boynton’s background and experience make him well qualified to serve as a Director.

Susan Bayh

Mrs. Susan B. Bayh is Independent Director of the Company. Ms. Bayh brings to NW Bio 25 years of experience relating to the pharmaceutical and biotech industries, including in immunotherapies for cancer. She has served on the Boards of Wellpoint, Inc., a Fortune 30 health insurance company with the Blue Cross brand in fifteen states, as well as on the board of eight public biotech companies, and three other companies, including in multiple leadership positions. Several of these biotech companies have been successfully acquired. She also served as in-house counsel at a major pharma company for five years, handling FDA pre-approval and post-approval matters. Ms. Bayh gained extensive experience with corporate governance and regulatory compliance, as well as a broad spectrum of business matters, including fundraising, corporate partnering, clinical trial requirements and execution, regulatory requirements relating to product approvals, orphan drugs, certification of manufacturing facilities, product marketing and commercialization, and product pricing and reimbursement. Ms. Bayh also brings specific experience in regard to personalized immunotherapies for cancer, as she served for a number of years on the Board of Dendreon, a biotech company that was an early pioneer in developing such therapies and the first company to obtain FDA approval for such a product. Ms. Bayh gained first-hand experience in regard to the challenges and pitfalls that can be involved in obtaining regulatory approval and reimbursement, and in commercializing such immunotherapies, as well as insights into potential improvements and solutions. Ms. Bayh's experience on the Dendreon Board has also prepared her well for dealing with the special challenges facing biotech companies.

Cofer Black

Amb. Cofer Black is Independent Director of the Company. Black is internationally recognized in the intelligence community and brings to NW Bio extensive experience in cybersecurity, counterintelligence, and investigations and related matters. Ambassador Black served a 28-year career in the CIA, including as Director of the Counterterrorist Center managing 1,300 professionals and an annual budget in excess of $1 billion . In that capacity, he served as the focal point for the intelligence community, supervised the Interagency Counterterrorism Board, was responsible for CIA all-source analysis, directed all CIA counterterrorism operations abroad, including covert action, and defined global intelligence strategy for the U.S. Ambassador Black was awarded the Distinguished Intelligence Medal (the CIA's highest award for achievement) as well as numerous other awards. Subsequently, in the private sector, from 2009 to the present Ambassador Black has served as Vice President for Global Operations at Raytheon Blackbird, advising the U.S. Government on security matters and equipment. He also serves as a Senior Advisor to the Razor's Edge Investment Fund, focusing on cutting edge technologies and equipment for the intelligence communities.

Robert Farmer

Mr. Robert A. Farmer is Independent Director of Northwest Biotherapeutics, Inc., since 2009. Mr. Farmer was appointed to the Board of Directors in December 2009. He served as the national treasurer of four presidential campaigns, including those for John Kerry, Bill Clinton, Michael Dukakis and John Glenn. In these roles he led fundraising of over $800 million. He served under Ron Brown as treasurer of the Democratic National Committee, and served for eight years as treasurer of the Democratic Governor’s Association. President Clinton appointed He as the United States Consul General to Bermuda, where he served from 1994 to 1999. He also had a successful career as an entrepreneur, including building his own publishing company, which he sold in 1983. He currently serves on the boards of directors of International Data Group, Dale Carnegie Associates, Sober Steering Sensors, LLC, Charlesbridge Publishing, and Haute Living. He is a graduate of Dartmouth College and Harvard Law School. We believe Mr. Farmer’s background and experience, as well as his service on other boards of directors, make him well qualified to serve as a Director.

Jerry Jasinowski

Mr. Jerry J. Jasinowski serves as Independent Director of Northwest Biotherapeutics, Inc., since April 16, 2012. Mr. Jasinowski was appointed to the Board of Directors in April 2012. He retired in 2007. Mr. Jasinowski currently serves on the Boards of Procurian and the Washington Tennis and Education Foundation and has held directorships in several other companies since 1990. From 2004 through 2007, He served as the President of the Manufacturing Institute, an organization dedicated to improving and expanding manufacturing in the United States, of which he was a founder. He was also the President and CEO of the National Association of Manufacturers, a trade association with 13,000 corporate members from 1990 to 2004. He holds an A.B. in Economics from Indiana University and an M.A. in Economics from Columbia University. We believe that Mr. Jasinowski’s extensive experience across a wide range of manufacturing, technology, and financial firms, including Fortune 1000 and Fortune 500 companies, make him well qualified to serve as a Director.

Navid Malik

Dr. Navid Malik serves as Independent Director of Northwest Biotherapeutics, Inc., since April 16, 2012. Dr. Malik was appointed to the Board of Directors in April 2012. He is the Head of Life Sciences Research at Cenkos Securities Plc. in the U.K., an independent specialist institutional securities firm. From September 2011 through January 2012, He was the Head of Life Sciences Research at Sanlam (Merchant Securities), a global financial services firm. He was Partner and Head of Life Sciences at Matrix Investment Banking Division, Matrix Group, a financial services firm in London, from December 2008 through September 2011. He was a Senior Pharmaceuticals and Biotechnology Analyst at Wimmer Financial LLP from September 2008 through December 2008, and was the Senior Life Sciences Analyst at Collins Stewart Plc from January 2005 through September 2008. In 2011, He was awarded two Starmine Awards (awarded each year by Thomson Reuters and the Financial Times): Number One Stock Picker in the European Pharmaceutical Sector, and Number Two Stock Picker in the U.K. and Ireland Healthcare Sector. He holds a Ph.D. in Drug Delivery within Pharmaceutical Sciences, as well as degrees in Biomedical Sciences Research (M.Sc.) and Biochemistry and Physiology (B.Sc., joint honors). He also holds an MBA in finance from the City University Business School, London. We believe that Dr. Malik’s extensive experience in the life sciences fields and investment banking sector make him well qualified to serve as a Director.

Lisa Sher

Basic Compensation